Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant platinum doublet + tislelizumab + voriconazole in resectable stage II–III NSCLC with pulmonary Aspergillus colonization
ChiCTR2600129648Phase 2Not yet recruiting
- Sponsor
- Jiangxi Cancer Hospital
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Jiangxi Cancer Hospital. Primary endpoint: Major pathological response rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600129648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129648.